as the Goulamina Project progresses towards development, the Company is continuing to build
relationships with various potential investment partners including lithium concentrate off-takers, lending institutions and institutional investors. A comprehensive range of funding options is open to the company and these are being investigated in order to secure the best arrangements to suit the Group’s funding requirements going forward.
You'd be forgiven for thinking our funding is all but secured.
Some really great wording in this HY report.
- Forums
- ASX - By Stock
- FFX
- Ann: 30 June 2018 Half-Year Financial Report
Ann: 30 June 2018 Half-Year Financial Report, page-10
-
- There are more pages in this discussion • 93 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add FFX (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online